CTA1-DD gene fusion protein |
|
Vaxjo ID |
48 |
|
Vaccine Adjuvant Name |
CTA1-DD gene fusion protein |
|
Adjuvant VO ID |
VO_0001290
|
|
Description |
The CTA1-DD fusion protein has proven equivalently potent as an adjuvant to the intact cholera holotoxin (CT) for humoral and cell-mediated immunity. CTA1-DD has successfully been evaluated as a systemic and mucosal adjuvant in mice, but not in humans (Vogel and Powell, 1995). |
|
Stage of Development |
Research |
|
Components |
The CTA1-DD protein consists of a genetically engineered fusion between genes encoding the cholera toxin A1-subunit and a dimer of a synthetic analogue of the D-fragment of Staph. aureus protein A (Vogel and Powell, 1995). |
|
Preparation |
The CTA1-DD plasmid is expressed in E. coli and the protein is purified to high purity on an IgGcolumn. Mutant CTA1-DD molecules have been constructed that do not ADP-ribosylate nor bind to Fcfragments of immunoglobulin (Vogel and Powell, 1995). |
|
Function |
CTA1-DD binds to B lymphocytes and is enriched to B cell follicles in the spleen after i.v injection. CTA1-DD, similar to CT, is used in soluble form simply by admixing with the unrelated protein antigen or, more effective, as chemical conjugates with unrelated protein antigen. The CTA1-DD can host immunogenic peptides inserted between the two moieties and acts then as a powerful targeted delivery and immunoenhancing vector (Vogel and Powell, 1995). |
|
Safety |
The CTA1-DD was found to be completely non-toxic, and had retained the adjuvant function of the intact holotoxin. Thus it effectively separates toxicity from adjuvanticity (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
